Predictors of AIDS-defining events among advanced naïve patients after HAART

Carlo Torti, Giuseppe Lapadula, Franco Maggiolo, Salvatore Casari, Fredy Suter, Lorenzo Minoli, Chiara Pezzoli, Massimo Di Pietro, Guglielmo Migliorino, Eugenia Quiros-Roldan, Nicoletta Ladisa, Laura Sighinolfi, Francesca Gatti, Giampiero Carosi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously. Method: ADE and mortality rates were assessed using Cox regression analyses. Variables were tested for prediction of ADE/death within the first 3 months of therapy and from month 3, thereafter. Results: 751 HIV-infected patients with 3 before HAART were followed for a median of 49 months. 207 new ADE occurred (7.06 [6.16-8.10] per 100 patient-years). ADE/deaths clustered within the first 3 months of treatment (106/207, 51%). Higher CD4+ T-cell counts during the follow-up (per loge cells/mm3: hazard ratio [HR] 0.51; 0.41-0.64; p <.001) and use of antiretroviral therapy (HR 0.38; 95% CI 0.21-0.69; p = .001) appeared to protect from ADE/death after month 3. Conversely, increasing follow-up with HIV RNA >400 copies/mL correlated with ADE/death (per month: HR 1.09; 95% CI 1.06-1.12; p = .001). Use of boosted protease inhibitors as first-line HAART and HCV-seropositivity were additional risk factors. Baseline CD4+ T-cell count and HIV RNA had a predominant impact in the first 3 months after HAART initiation. Conclusion: A careful monitoring of patients with low CD4+ is particularly necessary during the first few months of HAART. Length and extent of viral replication during the follow-up appeared to induce a significantly higher risk of HIV disease progression afterwards, implying that new drugs and new strategies aimed at ensuring long-term suppression of HIV RNA are of outstanding importance.

Original languageEnglish
Pages (from-to)112-120
Number of pages9
JournalHIV Clinical Trials
Volume8
Issue number3
DOIs
Publication statusPublished - May 2007

Fingerprint

Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
HIV
CD4 Lymphocyte Count
RNA
T-Lymphocytes
Physiologic Monitoring
Protease Inhibitors
Disease Progression
Regression Analysis
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • Advanced naïve
  • AIDS
  • Death
  • HAART
  • Late presenter
  • Predictors

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Torti, C., Lapadula, G., Maggiolo, F., Casari, S., Suter, F., Minoli, L., ... Carosi, G. (2007). Predictors of AIDS-defining events among advanced naïve patients after HAART. HIV Clinical Trials, 8(3), 112-120. https://doi.org/10.1310/hct0803-112

Predictors of AIDS-defining events among advanced naïve patients after HAART. / Torti, Carlo; Lapadula, Giuseppe; Maggiolo, Franco; Casari, Salvatore; Suter, Fredy; Minoli, Lorenzo; Pezzoli, Chiara; Di Pietro, Massimo; Migliorino, Guglielmo; Quiros-Roldan, Eugenia; Ladisa, Nicoletta; Sighinolfi, Laura; Gatti, Francesca; Carosi, Giampiero.

In: HIV Clinical Trials, Vol. 8, No. 3, 05.2007, p. 112-120.

Research output: Contribution to journalArticle

Torti, C, Lapadula, G, Maggiolo, F, Casari, S, Suter, F, Minoli, L, Pezzoli, C, Di Pietro, M, Migliorino, G, Quiros-Roldan, E, Ladisa, N, Sighinolfi, L, Gatti, F & Carosi, G 2007, 'Predictors of AIDS-defining events among advanced naïve patients after HAART', HIV Clinical Trials, vol. 8, no. 3, pp. 112-120. https://doi.org/10.1310/hct0803-112
Torti, Carlo ; Lapadula, Giuseppe ; Maggiolo, Franco ; Casari, Salvatore ; Suter, Fredy ; Minoli, Lorenzo ; Pezzoli, Chiara ; Di Pietro, Massimo ; Migliorino, Guglielmo ; Quiros-Roldan, Eugenia ; Ladisa, Nicoletta ; Sighinolfi, Laura ; Gatti, Francesca ; Carosi, Giampiero. / Predictors of AIDS-defining events among advanced naïve patients after HAART. In: HIV Clinical Trials. 2007 ; Vol. 8, No. 3. pp. 112-120.
@article{b8041c79de4f4af9a14c0c3d41500ca4,
title = "Predictors of AIDS-defining events among advanced na{\"i}ve patients after HAART",
abstract = "Background: Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously. Method: ADE and mortality rates were assessed using Cox regression analyses. Variables were tested for prediction of ADE/death within the first 3 months of therapy and from month 3, thereafter. Results: 751 HIV-infected patients with 3 before HAART were followed for a median of 49 months. 207 new ADE occurred (7.06 [6.16-8.10] per 100 patient-years). ADE/deaths clustered within the first 3 months of treatment (106/207, 51{\%}). Higher CD4+ T-cell counts during the follow-up (per loge cells/mm3: hazard ratio [HR] 0.51; 0.41-0.64; p <.001) and use of antiretroviral therapy (HR 0.38; 95{\%} CI 0.21-0.69; p = .001) appeared to protect from ADE/death after month 3. Conversely, increasing follow-up with HIV RNA >400 copies/mL correlated with ADE/death (per month: HR 1.09; 95{\%} CI 1.06-1.12; p = .001). Use of boosted protease inhibitors as first-line HAART and HCV-seropositivity were additional risk factors. Baseline CD4+ T-cell count and HIV RNA had a predominant impact in the first 3 months after HAART initiation. Conclusion: A careful monitoring of patients with low CD4+ is particularly necessary during the first few months of HAART. Length and extent of viral replication during the follow-up appeared to induce a significantly higher risk of HIV disease progression afterwards, implying that new drugs and new strategies aimed at ensuring long-term suppression of HIV RNA are of outstanding importance.",
keywords = "Advanced na{\"i}ve, AIDS, Death, HAART, Late presenter, Predictors",
author = "Carlo Torti and Giuseppe Lapadula and Franco Maggiolo and Salvatore Casari and Fredy Suter and Lorenzo Minoli and Chiara Pezzoli and {Di Pietro}, Massimo and Guglielmo Migliorino and Eugenia Quiros-Roldan and Nicoletta Ladisa and Laura Sighinolfi and Francesca Gatti and Giampiero Carosi",
year = "2007",
month = "5",
doi = "10.1310/hct0803-112",
language = "English",
volume = "8",
pages = "112--120",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Predictors of AIDS-defining events among advanced naïve patients after HAART

AU - Torti, Carlo

AU - Lapadula, Giuseppe

AU - Maggiolo, Franco

AU - Casari, Salvatore

AU - Suter, Fredy

AU - Minoli, Lorenzo

AU - Pezzoli, Chiara

AU - Di Pietro, Massimo

AU - Migliorino, Guglielmo

AU - Quiros-Roldan, Eugenia

AU - Ladisa, Nicoletta

AU - Sighinolfi, Laura

AU - Gatti, Francesca

AU - Carosi, Giampiero

PY - 2007/5

Y1 - 2007/5

N2 - Background: Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously. Method: ADE and mortality rates were assessed using Cox regression analyses. Variables were tested for prediction of ADE/death within the first 3 months of therapy and from month 3, thereafter. Results: 751 HIV-infected patients with 3 before HAART were followed for a median of 49 months. 207 new ADE occurred (7.06 [6.16-8.10] per 100 patient-years). ADE/deaths clustered within the first 3 months of treatment (106/207, 51%). Higher CD4+ T-cell counts during the follow-up (per loge cells/mm3: hazard ratio [HR] 0.51; 0.41-0.64; p <.001) and use of antiretroviral therapy (HR 0.38; 95% CI 0.21-0.69; p = .001) appeared to protect from ADE/death after month 3. Conversely, increasing follow-up with HIV RNA >400 copies/mL correlated with ADE/death (per month: HR 1.09; 95% CI 1.06-1.12; p = .001). Use of boosted protease inhibitors as first-line HAART and HCV-seropositivity were additional risk factors. Baseline CD4+ T-cell count and HIV RNA had a predominant impact in the first 3 months after HAART initiation. Conclusion: A careful monitoring of patients with low CD4+ is particularly necessary during the first few months of HAART. Length and extent of viral replication during the follow-up appeared to induce a significantly higher risk of HIV disease progression afterwards, implying that new drugs and new strategies aimed at ensuring long-term suppression of HIV RNA are of outstanding importance.

AB - Background: Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously. Method: ADE and mortality rates were assessed using Cox regression analyses. Variables were tested for prediction of ADE/death within the first 3 months of therapy and from month 3, thereafter. Results: 751 HIV-infected patients with 3 before HAART were followed for a median of 49 months. 207 new ADE occurred (7.06 [6.16-8.10] per 100 patient-years). ADE/deaths clustered within the first 3 months of treatment (106/207, 51%). Higher CD4+ T-cell counts during the follow-up (per loge cells/mm3: hazard ratio [HR] 0.51; 0.41-0.64; p <.001) and use of antiretroviral therapy (HR 0.38; 95% CI 0.21-0.69; p = .001) appeared to protect from ADE/death after month 3. Conversely, increasing follow-up with HIV RNA >400 copies/mL correlated with ADE/death (per month: HR 1.09; 95% CI 1.06-1.12; p = .001). Use of boosted protease inhibitors as first-line HAART and HCV-seropositivity were additional risk factors. Baseline CD4+ T-cell count and HIV RNA had a predominant impact in the first 3 months after HAART initiation. Conclusion: A careful monitoring of patients with low CD4+ is particularly necessary during the first few months of HAART. Length and extent of viral replication during the follow-up appeared to induce a significantly higher risk of HIV disease progression afterwards, implying that new drugs and new strategies aimed at ensuring long-term suppression of HIV RNA are of outstanding importance.

KW - Advanced naïve

KW - AIDS

KW - Death

KW - HAART

KW - Late presenter

KW - Predictors

UR - http://www.scopus.com/inward/record.url?scp=34547358963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547358963&partnerID=8YFLogxK

U2 - 10.1310/hct0803-112

DO - 10.1310/hct0803-112

M3 - Article

C2 - 17621458

AN - SCOPUS:34547358963

VL - 8

SP - 112

EP - 120

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 3

ER -